ArticleBiochemistry and biophysics reports2026
Overexpression of regenerating islet-derived type 4 isoform 2 increases colorectal cancer cell proliferation.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regenerating islet-derived type 4 (REG4) is highly expressed in various cancers, including colorectal cancer (CRC). REG4 has been reported to promote cancer cell proliferation, contribute to treatment resistance, and be associated with poor prognosis in CRC. In humans, this protein has two isoforms that are translated from three RNA-splicing variants. However, previous studies have primarily focused on isoform 1 and have not examined the function of isoform 2. Therefore, in the present study, we aimed to investigate the effects of REG4 isoform 2 on colon cancer cell proliferation. Real-time polymerase chain reaction (RT-qPCR) revealed higher REG4 isoform 2 expression in colon cancer cell lines (DLD-1, HCT116, and HT29) than in normal tissue-derived cell lines (HDLECs, HME1, HUVECs, and TIG114), similar to that of REG4 isoform 1. Moreover, REG4 isoform 2 overexpression significantly enhanced the proliferation of colon cancer-derived HCT116 cells in a WST-1 assay under low-serum conditions and in a soft agar colony formation assay. In NOD/SCID mice, tumor volumes tended to be larger in the REG4 isoform 2-overexpressing group than in the controls, although the difference did not reach statistical significance. Furthermore, in a subset of patients, the expression of this isoform in CRC tissues was higher than that in the adjacent normal tissues in human specimens. These results suggest that REG4 isoform 2, similar to isoform 1, is associated with enhanced proliferative properties of colon cancer cells and highlight the need for further investigation of isoform 2 in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.